{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-290176","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.889216+00:00","generated_at":"2026-06-21T14:04:44.055080+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones","bullets":["CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.","Tiered royalties from high single digit to low-teen percentages on global net sales of licensed products.","Collaboration uses CytomX's Probody platform and Regeneron's Veloci-Bi bispecific platform for conditionally-activated cancer therapies.","Regeneron fully funds all preclinical, development, manufacturing, and commercialization activities worldwide.","CytomX grants exclusive worldwide royalty-bearing license to Regeneron for oncology; Regeneron may terminate programs on 30 days' notice after 2 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-290176","json":"https://secwatch.observer/filing/0001193125-22-290176.json","markdown":"https://secwatch.observer/filing/0001193125-22-290176.md","text":"https://secwatch.observer/filing/0001193125-22-290176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/0001193125-22-290176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/d402086d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:04:44.055080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19dd68dcdee56cdd0ee0d9b2cb597c74b4c33185","claim":"CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with Regeneron Pharmaceuticals Inc. valued at $30 million (effective 2022-11-16).","evidence_excerpt":"On November 16, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with Regeneron Pharmaceuticals Inc. (“Regeneron”), pursuant to which the Company and Regeneron will collaborate on the creation of conditionally-activated investigational bispecific cancer therapies utilizing the Company’s Probody ® therapeutic platform and Regeneron’s Veloci-Bi ® bispecific antibody development platform.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/0001193125-22-290176-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Regeneron Pharmaceuticals Inc."},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2022-11-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}